Clinical trials: Lung
Pulmonary Disease, Chronic Obstructive
HHHFA in COPD Patients, With Chronic Bronchitis
Heated, humidified high-flow air (HHHFA) devices improve airway clearance. HHHFA use for an average of 1.6 hours a day in COPD patients with chronic bronchitis improves health-related quality of life, lung function, and delays…
- Trial name
- NCT03959982
- Testing
- HHHFA Device, Spirometry, 6-minute walk
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Spyridon Fortis
Coronavirus Disease-2019 (COVID-19) Prevention
A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive
The primary purpose of this study is to assess the safety, reactogenicity, and humoral immune response of Ad26.COV2.S administered intramuscularly (IM) as a 1-dose schedule or as a 2-dose schedule (56-day interval) in adolescents.
- Trial name
- HORIZON 2 (NCT05007080)
- Testing
- Ad26.COV2.S
- Where
- 18 sites in Argentina, Brazil and 3 more
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
SARS-CoV-2 (COVID-19) Severe Pneumonia
Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
To evaluate the safety and preliminary efficacy of efzofitimod, compared to placebo matched to efzofitimod, in hospitalized participants with SARS-CoV-2 (COVID-19) severe pneumonia not requiring mechanical ventilation.
- Trial name
- NCT04412668
- Testing
- Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- aTyr Pharma, Inc.
Carcinoma, Non-Small-Cell Lung
Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC
The purpose of this study is to evaluate the objective tumor response rate (based on the RECIST criteria) to SNS-595 as a second-line therapy in patients with advanced NSCLC.
- Trial name
- NCT00252382
- Testing
- SNS-595 Injection
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sunesis Pharmaceuticals
NSCLC (Non-small Cell Lung Carcinoma)
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
The purpose of this study was to determine if ruxolitinib, in combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is…
- Trial name
- NCT02119650
- Testing
- Ruxolitinib, Pemetrexed, Cisplatin
- Where
- 30 sites in United States
- Volunteers
- 76 people
- Sponsor
- Incyte Corporation
Pneumonia, Ventilator-Associated
Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia
The purpose of this study is to determine if administering inhaled antibiotics directly into the lungs in conjunction with intravenous (IV) antibiotics leads to better outcomes and decreased recurrence of ventilator associated…
- Trial name
- AAINTVAP (NCT02478710)
- Testing
- Aerosolized Tobramycin or Vancomycin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wright State University
Non-Small Cell Lung Cancer, Urothelial Cancer
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum…
- Trial name
- NCT03472560
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736)
- Where
- 39 sites in United States, Hungary and 6 more
- Volunteers
- 61 people
- Sponsor
- Pfizer
Cystic Fibrosis
A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy
This study evaluate the long-term safety and tolerability of elexacaftor (ELX)/tezacaftor (TEZ)/ ivacaftor (IVA) triple combination (TC) in participants with cystic fibrosis (CF) who are homozygous for F508del.
- Trial name
- NCT04362761
- Testing
- ELX/TEZ/IVA, IVA
- Where
- 29 sites in Australia, Belgium and 2 more
- Volunteers
- 172 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
COVID-19
COVID-19 PrEP HCW HCQ Study
Off label study to evaluate the efficacy of HCQ for pre-exposure prophylaxis (PrEP) to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
- Trial name
- NCT04354870
- Testing
- Hydroxychloroquine (HCQ)
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- NYU Langone Health
Covid19, SARS-CoV-2 Infection
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
A Trial of GC4419 in Patients with Critical Illness due to COVID-19
- Trial name
- NCT04555096
- Testing
- GC4419
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Galera Therapeutics, Inc.
Tracheitis, Tracheobronchitis
Evaluation of Effectiveness of the Treatment After Repeated Administration of Klacid®SR
This post-marketing observational study (PMOS) will be conducted in a prospective, single-arm, single-country, multicenter format.
- Conditions
- Tracheitis, Tracheobronchitis, Bronchitis, Chronic Bronchitis
- Trial name
- NCT01130883
- Where
- 135 sites in Czechia
- Volunteers
- 3,130 people
- Sponsor
- Abbott
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate, after 1 week of dosing, the efficacy and safety of PT003 compared with its individual components (PT001 and PT005), placebo and two active comparators to demonstrate superiority of the…
- Trial name
- NCT01085045
- Testing
- PT003 MDI, PT005 MDI, Tiotropium bromide 18 μg (Spiriva Handihaler®)
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 118 people
- Sponsor
- Pearl Therapeutics, Inc.
Cystic Fibrosis
Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study
Protocol 0000498: Multicenter, open label study to evaluate the effect of sustained RELiZORB (immobilized lipase) cartridge use during enteral feeding on fat absorption, as well as safety and tolerability of sustained RELiZORB…
- Trial name
- ASSURE (NCT02750501)
- Testing
- RELiZORB (immobilized lipase) cartridge, Impact Peptide 1.5
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Alcresta Therapeutics, Inc.
Lung Cancer
Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review
This is a longitudinal, consecutive case-series, multi-center study with mixed prospective and retrospective data collection. Data will be collected from eligible adults with EGFR mutation-positive advanced non-small cell lung…
- Trial name
- NCT04609319
- Testing
- Dacomitinib
- Where
- 14 sites in China, India and 1 more
- Volunteers
- 307 people
- Sponsor
- Pfizer
Pulmonary TB
A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis
This trial will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of multiple oral doses of OPC-167832 in participants with uncomplicated, smear-positive, drug-susceptible pulmonary tuberculosis (TB).
- Trial name
- NCT03678688
- Testing
- 10 mg OPC-167832, 30 mg OPC-167832, 90 mg OPC-167832
- Where
- 3 sites in South Africa
- Volunteers
- 122 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Non-squamous Non-small Cell Lung Cancer
Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer
Multi-center, open, randomized (parallel) and comparative phase III. Eligible patients will receive bevacizumab + chemotherapy for a minimum of 4 cycles followed by bevacizumab (+ pemetrexed, if appropriate) maintenance therapy…
- Trial name
- 65plus (NCT00976456)
- Testing
- Bevacizumab + Pemetrexed, Bevacizumab + Pemetrexed + Carboplatin
- Where
- Germany
- Volunteers
- 271 people
- Sponsor
- PD Dr. med. Wolfgang Schuette
Chronic Lymphocytic Leukemia
Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia
The purpose of this study is to determine whether on course (6 cycles) of consolidation therapy with Revlimid can shrink or slow the growth of Chronic Lymphocytic Leukemia (CLL) in the bone marrow.
- Trial name
- NCT01600053
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Thomas Kipps
Oxygen Toxicity
Pulmonary Function After Hyperbaric Oxygen Therapy
Patients receiving hyperbaric oxygen therapy (HBOT) for any indication at the Hyperbaric Medicine Unit (University Health Network, Toronto, ON, Canada) from 2016-2021 were recruited to this prospective cohort study.
- Trial name
- NCT05088772
- Testing
- Hyperbaric Oxygen Therapy
- Where
- Canada
- Volunteers
- 86 people
- Sponsor
- University of Toronto
Gastroesophageal Reflux, Asthma
Elucidation of Acid-Induced Pulmonary Inflammation
This study will evaluate how heartburn may lead to different types of inflammation in one's airways. Additionally, the study will determine whether aggressive treatment of heartburn results in improvement in both symptoms of…
- Trial name
- NCT00361972
- Testing
- lansoprazole
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Utah
COPD, COPD Exacerbation
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD.
- Conditions
- COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders
- Trial name
- NCT01443845
- Testing
- Roflumilast
- Where
- 338 sites in United States, Argentina and 15 more
- Volunteers
- 2,354 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.